Search research articles
Contact Us
Filters
Showing results (101-110 of 131) with videos related to
Page
of 14
Sort By:
Brain, Behavior, and Immunity
|
August 5, 2023
Multi-omics approaches in psychoneuroimmunology and health research: Conceptual considerations and methodological recommendations
Summer Mengelkoch, Sophia Miryam Schüssler-Fiorenza Rose, Ziv Lautman, et al.
Journal of Clinical Pharmacology
|
June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies
Tae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.
Cancer Research
|
February 1, 1988
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay
M C Alley, D A Scudiero, A Monks, et al.
Plos One
|
February 26, 2013
A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept
Susan D Mertins, Dominic A Scudiero, Melinda G Hollingshead, et al.
Protein Engineering, Design & Selection : PEDS
|
January 26, 2018
Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability
D Sussman, L Westendorf, D W Meyer, et al.
Cancer Research
|
October 1, 1987
Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice
T L McLemore, M C Liu, P C Blacker, et al.
Molecular Cancer Therapeutics
|
June 24, 2004
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells
Andrea I Loaiza-Pérez, Susan Kenney, Jamie Boswell, et al.
Cancer Chemotherapy and Pharmacology
|
April 18, 2022
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl
Hao Sun, Kristen A Cardinal, Larry Wienkers, et al.
Nature Communications
|
November 30, 2022
Analysis of the first genetic engineering attribution challenge
Oliver M Crook, Kelsey Lane Warmbrod, Greg Lipstein, et al.
Molecular Cancer Therapeutics
|
December 7, 2002
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles
Tracey D Bradshaw, Michael C Bibby, John A Double, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 131) with videos related to
Sort By:
Page
of 14
Brain, Behavior, and Immunity
|
August 5, 2023
Multi-omics approaches in psychoneuroimmunology and health research: Conceptual considerations and methodological recommendations
Summer Mengelkoch, Sophia Miryam Schüssler-Fiorenza Rose, Ziv Lautman, et al.
Journal of Clinical Pharmacology
|
June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies
Tae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.
Cancer Research
|
February 1, 1988
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay
M C Alley, D A Scudiero, A Monks, et al.
Plos One
|
February 26, 2013
A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept
Susan D Mertins, Dominic A Scudiero, Melinda G Hollingshead, et al.
Protein Engineering, Design & Selection : PEDS
|
January 26, 2018
Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability
D Sussman, L Westendorf, D W Meyer, et al.
Cancer Research
|
October 1, 1987
Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice
T L McLemore, M C Liu, P C Blacker, et al.
Molecular Cancer Therapeutics
|
June 24, 2004
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells
Andrea I Loaiza-Pérez, Susan Kenney, Jamie Boswell, et al.
Cancer Chemotherapy and Pharmacology
|
April 18, 2022
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl
Hao Sun, Kristen A Cardinal, Larry Wienkers, et al.
Nature Communications
|
November 30, 2022
Analysis of the first genetic engineering attribution challenge
Oliver M Crook, Kelsey Lane Warmbrod, Greg Lipstein, et al.
Molecular Cancer Therapeutics
|
December 7, 2002
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles
Tracey D Bradshaw, Michael C Bibby, John A Double, et al.
Page
of 14